Harvard University is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Location
Cambridge, Massachusetts, USA
Type
Private Research University
Notable Centers
Harvard Medical School, Harvard T.H. Chan School of Public Health
Harvard University is the oldest institution of higher education in the United States and one of the world's most prestigious research universities. Located in Cambridge, Massachusetts, Harvard has been at the forefront of neurodegenerative disease research for decades, with groundbreaking discoveries in Alzheimer's disease, Parkinson's disease, and other neurological conditions.
Harvard Medical School (HMS) is home to some of the world's leading neuroscientists and neurologists conducting neurodegeneration research. Key research areas include:
- Alzheimer's Disease Research: Multiple laboratories focus on amyloid biology, tau pathology, neuroinflammation, and therapeutic development
- Parkinson's Disease Research: Studies on alpha-synuclein aggregation, dopaminergic neuron degeneration, and movement disorders
- Neurobiology of Aging: Understanding the cellular and molecular mechanisms of brain aging
Harvard hosts several dedicated Alzheimer's disease research centers, including:
- Massachusetts Alzheimer's Disease Research Center: NIH-funded center conducting clinical and basic research
- Harvard Aging Brain Study: Longitudinal study identifying biomarkers of preclinical Alzheimer's
- The Laboratory of Neurobiology at Harvard Medical School
- Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital
- Harvard NeuroDiscovery Center
- Discovery of Amyloid Precursor Protein (APP): Harvard researchers identified and characterized APP, the source of amyloid-beta plaques
- Early Tau Research: Pioneering studies on tau protein and neurofibrillary tangles
- Genetic Discoveries: Identification of familial Alzheimer's disease genes and risk factors
- Amyloid and Tau Biology: Understanding the pathogenesis of protein aggregation
- Neuroinflammation: Role of microglia and immune response in neurodegeneration
- Biomarker Development: CSF and blood biomarkers for early detection
- Therapeutic Development: Drug candidates targeting various disease mechanisms
- Stem Cell Models: Induced pluripotent stem cell (iPSC) models of neurodegeneration
Harvard-affiliated researchers working on neurodegenerative diseases include:
- Dr. Rudy Tanzi: Discovery of Alzheimer's disease genes, gamma-secretase research
- Dr. Steven Hyman: Former director of NIMH, focus on neuropsychiatric disorders
- Dr. John Kwok: Mitochondrial dysfunction in neurodegeneration
- Dr. Christina R. White: Tau pathology and therapeutic development
- Dr. Bradley Hyman: Alzheimer's disease clinical and basic research
Harvard's teaching hospitals involved in neurodegenerative disease research:
- Massachusetts General Hospital: Founding member of Harvard Medical School
- Brigham and Women's Hospital: Home to the Ann Romney Center
- Beth Israel Deaconess Medical Center: Alzheimer's disease research programs
- McLean Hospital: Psychiatric and neurodegenerative research
¶ Training and Education
Harvard offers extensive training in neurodegenerative disease research:
- PhD programs in Neuroscience, Cell Biology, and Genetics
- MD/PhD training in neurologic diseases
- Postdoctoral fellowships in neurodegeneration laboratories
- Clinical fellowships in behavioral neurology and movement disorders
The study of Harvard University has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Tanzi RE, et al. (2012). Amyloid precursor protein and gamma-secretase: So many variants, so many questions. Nature Reviews Neuroscience, 13(11), 703-704.
- Hyman BT, et al. (2012). National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimer's & Dementia, 8(1), 1-13.
- Karch CM, et al. (2012). The role of tau pathology in the pathogenesis of Alzheimer's disease. Journal of Alzheimer's Disease, 33(1), S123-S139.
- Querfurth HW, LaFerla FM. (2010). Alzheimer's disease. New England Journal of Medicine, 362(4), 329-344.
- Selkoe DJ, Hardy J. (2016). The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Molecular Medicine, 8(6), 595-608.